- Salary
- $120K–$135K
- Hiring from
- United States
- Work type
- Hybrid
- Posted
625,606 remote jobs, straight from company career pages
100% free · New jobs every minute
Show job descriptionHide job description
Company:
0750 Stemline Therapeutics IncContract Type:
PermanentJoin us in shaping the future of Menarini - with passion, integrity, and a deep commitment to people.
About Menarini Group - Menarini is a leading international biopharmaceutical company committed to advancing health through innovation, research, and quality. For more than 135 years, we have worked to improve patients’ lives across a broad range of therapeutic areas through our dedication to science, integrity, and care for people. With a strong foundation in scientific excellence and a purpose-driven culture, Menarini offers diverse career opportunities for professionals eager to make a meaningful impact on global health.
Position Title: Senior Financial Analyst - Corporate FP&A, Systems & COGS
Reports To: Senior Director, US Controller
Overview:
The Senior Financial Analyst – Corporate FP&A, Systems & COGS is an analytical and operational business partner supporting the Menarini Stemline Oncology finance organization. This role is responsible for supporting financial planning cycles (annual budget, reforecasts, and strategic plan) for corporate overheads/operating expenses (OpEx) and Cost of Goods Sold (COGS). Additionally, this role acts as a finance systems super-user, ensuring data integrity, building standardized reporting packages, and optimizing data extraction workflows between SAP S/4HANA and CCH Tagetik.
Responsibilities:
- Support the annual budgeting, rolling forecast, and strategic planning processes for corporate overheads, departmental OpEx, and Cost of Goods Sold (COGS) in alignment with Menarini reporting guidelines.
- Serve as a key finance super-user across SAP S/4HANA and CCH Tagetik, assisting with monthly data reconciliations, planning template uploads, and report generation.
- Assist in monthly COGS and inventory tracking, reconciling manufacturing and third-party supply chain expenses against budgets and production milestones.
- Prepare monthly OpEx variance analysis (Actuals vs. Budget/Forecast) across functional cost centers, identifying key drivers of variances and providing commentary for leadership reviews.
- Review purchase orders, operational commitments, and vendor invoices to ensure accurate classification across cost centers, accounts, and WBS elements.
- Partner with the accounting team during the month-end close by preparing routine accrual entries, investigating unbilled spend, and providing GL-level variance schedules.
- Maintain and enhance recurring Excel and dashboard reporting models to streamline weekly and monthly financial reporting deliverables for senior leadership.
- Provide audit support by compiling sample documentation, schedules, and process workflows for internal and external auditors as required.
- Execute ad-hoc financial analysis and participate in cross-functional finance process improvement initiatives.
Qualifications:
- Bachelor’s degree in Finance, Accounting, Economics, or Business Administration required.
- 3 to 5+ years of progressive experience in FP&A, corporate finance, or operational accounting, preferably within the pharmaceutical, biotechnology, or life sciences sector.
- Hands-on proficiency using ERP systems (SAP S/4HANA preferred) and enterprise planning/EPM tools (CCH Tagetik, Hyperion/Essbase, Cognos, or OneStream).
- Foundational understanding of corporate overhead budgeting, GL accounting principles (accruals/prepaids), and basic Cost of Goods Sold / inventory tracking.
- Advanced Microsoft Excel skills (xlookup/vlookup, sumifs, index/match, pivot tables, and multi-tab modeling); proficiency in PowerPoint.
- Detail-oriented with strong analytical and problem-solving skills; ability to manage multiple deliverables in a dynamic, deadline-driven setting.
- Solid communication and interpersonal skills, with the ability to collaborate effectively with cross-functional business partners and accounting teams.
***NOTE - Role will require to be on-site weekly at NYC office***
Please note: This position is classified as a corporate office position. In accordance with the New York state employer convenience rule, Stemline will withhold New York state income taxes for all corporate office employees, regardless of whether these employees work in New York or remotely.
Base Salary Range of $120,000 - 135,000. Menarini Stemline offers generous compensation and benefits packages, including, Fidelity 401(k) (with company match), PPO and HDHP insurance plans, Company paid Basic Life & AD&D insurance and pre-tax FSA/HSA programs.
Menarini Stemline is committed to creating an inclusive environment for all employees. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran. Reasonable accommodations may be made to enable qualified individuals with disabilities to perform the essential functions. To request an accommodation, please contact hrus@menarinistemline. com prior to your interview.
Base Salary Range of:
90000Menarini Stemline offers generous compensation and benefits packages, including Fidelity 401(k) (with company match), Healthcare insurance, Company-paid Basic Life & AD&D insurance and pre-tax FSA/HSA programs.
Menarini Stemline is committed to creating an inclusive environment for all employees. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran. Reasonable accommodations may be made to enable qualified individuals with disabilities to perform the essential functions.
The Company
Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.
The Menarini Group is present in 70 countries and our products are sold in 140 locations around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market.
Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents.
Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of haematological and solid tumours. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications, including acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML), and myelofibrosis (MF).
Additionally, Menarini received exclusive rights to commercialise Selinexor for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries. Menarini has signed an exclusive licensing agreement with Karyopharm Therapeutics for the rights to commercialise an innovative therapeutic option in Europe, Latin America, Turkey, Russia, and CIS countries. Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear export compound for the treatment of hematologic cancers and solid tumours. It is already marketed in the US for multiple myeloma and is under development for solid tumour indications. Selinexor is registered in the EU for both early and late lines.
Menarini entered into a global licence agreement with Radius Health to complete the development of Elacestrant, an oral SERD in late-stage Phase 3 development for hormone receptor-positive advanced breast cancer. Following a successful phase 3 study, Menarini Stemline received FDA approval in January 2023 under priority review and successfully oversaw a strong launch in February to the US market with the EMA review process concluded positively in September 2023.
Menarini’s commitment to oncology is also reflected in the investments made in the liquid biopsy diagnostic field through its affiliate Menarini Silicon Biosystems (MSB), a pioneer in rare cell analysis and non-invasive, advanced diagnostic solutions. MSB’s CELLSEARCH Circulating Tumour Cell (CTC) Test is the first and only clinically validated blood test cleared by the U.S. Food & Drug Administration (FDA) for detecting and counting CTCs in metastatic breast, prostate, and colorectal cancer when used in conjunction with other clinical monitoring methods.
Since 2021, MSB has offered in the US a menu of non-invasive Laboratory Developed Tests (LDTs) provided through its CLIA/CAP accredited US-based Lab. The services include CMC enumeration, CTC enumeration and PDL-1/HER2 biomarker and offer a minimally invasive approach to follow cancer patient’s therapeutic journey.
In 2022, the company launched the CELLSEARCH® Circulating Multiple Myeloma Cell (CMMC) Enumeration LDT, the first-of-its-kind, which directly measures levels of plasma cells in the blood of patients. This test provides new, complementary information to that of the bone marrow biopsy and other standard-of-care measures. Due to its minimally invasive nature, it can be performed serially to assess plasma cell burden without requiring repeated bone marrow biopsies.
Menarini's vision and uniqueness in oncology is to bring together innovative therapeutic solutions and advanced liquid biopsy-based diagnostics for faster, more effective and precise patient management.
It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline's Oncology business.
For more details on how we handle your data, please refer to our Privacy Policy.
About Us
Become part of a story that began in 1886 with a small pharmacy in Naples and has grown into a global presence in over 140 countries,
improving lives through innovative medicines, diagnostics, and healthcare solutions.
At Menarini, you're not just building a career-you’re making a real impact. We put people first-patients and employees alike-
and foster a culture where ideas are valued, growth is supported, and the future of health is shaped together.
Discover how your ambition can thrive in an environment driven by purpose, passion, and progress.
Together, we make health a lifelong commitment.